Dj The 3 Best Chip Stocks To Buy For 2026, According To An Analyst - Barrons.Com

Investing.com -- Trinity Biotech plc (NASDAQ:TRIB) stock gained 3.7% on Monday following the company’s announcement of regulatory clearances for its next-generation high-capacity HbA1c column system in multiple countries, including the United States.

The biotechnology company said its upgraded system for the Premier Hb9210 analyzer is now available in more than 10 countries, offering up to four times the testing capacity compared to the existing column system. The new technology enhances operational efficiency through increased column stability and reduced maintenance requirements, creating a more efficient workflow for clinical laboratories.

Trinity Biotech’s next-generation system is designed to strengthen the company’s position in the global laboratory HbA1c market, which is currently estimated to be worth over $2 billion annually and projected to exceed $3.5 billion by 2030. The growth is primarily driven by the increasing prevalence of diabetes.

"Launching this advanced system in key markets, including the U.S., positions Trinity Biotech to capture further growth opportunities in the global diabetes care segment," said John Gillard, CEO and President of Trinity Biotech. "The combination of higher capacity, reduced downtime, and automation creates a compelling value proposition for laboratories, and we expect strong adoption in key markets to drive long-term shareholder value."

The company’s Premier Hb9210 solution continues to be recognized as a gold standard in HbA1c testing, with peer-reviewed studies confirming its clinical performance. Trinity Biotech is working with customers and regulatory authorities to expand availability into additional countries.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Jefferies upgraded semiconductor equipment maker KLA Corp. to Buy in a note to clients on Monday, citing accelerating AI-driven spending and a stronger outlook for leading-edge and advanced packaging demand.

In its 2026 outlook, Jefferies said “AI remains our favorite group” as hyperscaler capital expenditure accelerates and ASIC adoption inflects, driving a multi-year runway for semiconductor capital equipment. 

Against that backdrop, Jefferies is “upgrading KLAC to Buy on stronger Leading edge/packaging outlook,” while maintaining a constructive view on wafer fab equipment (WFE) growth into 2026 and 2027.

Jefferies noted that “AI continues to drive spend with WFE accelerating into C26/C27,” supporting higher demand across leading-edge foundry, memory and packaging. 

The firm highlighted KLA’s “outsized exposure to the Leading Edge,” arguing that the company is well-positioned as AI pushes capacity additions starting in the second half of 2026.

As part of the upgrade, Jefferies raised its price target on KLA to $1,500, based on “30x C28 EPS of $50,” and said the stock has seen a “recent relative multiple reset as premium closing vs peers.” 

Jefferies also lifted its revenue forecasts, raising estimates to $14.0 billion for 2026 and $15.5 billion for 2027, above Street expectations.

Investing.com -- Aytu BioPharma (NASDAQ:AYTU) stock gained 2.6% on Monday after the company announced the commercial availability of its newly approved depression treatment EXXUA in the United States.

The pharmaceutical company said EXXUA, the first and only 5HT1a agonist approved by the FDA for major depressive disorder (MDD), is now available through participating Aytu RxConnect pharmacies. This enables immediate access through the company’s patient access program, with distribution through major U.S. wholesalers underway to expand nationwide availability in the coming weeks.

EXXUA represents a new approach to treating MDD, which affects an estimated 21 million Americans. According to the company, the drug demonstrated significant improvement in depression symptoms across clinical trials involving more than 5,000 patients.

"We are thrilled to have achieved this significant milestone with EXXUA now officially available in the United States as a new treatment option for the estimated 21 million Americans suffering from major depressive disorder," said Josh Disbrow, Chief Executive Officer of Aytu.

The company highlighted EXXUA’s distinctive clinical profile, noting it has no warnings or adverse events related to sexual dysfunction and no clinically significant weight gain compared to placebo in trials. These characteristics could differentiate it from many existing depression medications that often come with such side effects.

Aytu emphasized that ensuring patient access and affordability remains its top priority for the newly launched treatment. Information about the product and participating pharmacies is available on EXXUA.com.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.